Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15303789 | 0.80 | KDM4E (0.83) | KDM4EKMT2APOLBALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL10334554 | 0.78 | KDM4E (0.81) | KDM4EKMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL2764119 | 0.78 | HPGD (0.59) | KDM4EKMT2APOLBALDH1A1LMNA | |
| SCHEMBL10334481 | 0.78 | POLB (0.84) | KDM4EKMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL10447618 | 0.77 | ALDH1A1 (0.70) | KDM4EPOLBALDH1A1L3MBTL1LMNA | |
| SCHEMBL24109288 | 0.77 | KDM4E (0.46) | KDM4EKMT2AALDH1A1L3MBTL1LMNA | |
| SCHEMBL24109056 | 0.76 | KDM4E (0.46) | KDM4EKMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL11847732 | 0.75 | KDM4E (0.76) | KDM4EKMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL2765033 | 0.75 | HPGD (0.56) | KDM4EKMT2APOLBALDH1A1LMNA | |
| SCHEMBL20338952 | 0.75 | KMT2A (0.53) | KMT2AALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | KDM4E 1531/4885KMT2A 2463/4885POLB 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.